Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMO | O15229 | 4/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.43 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.43 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.43 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.43 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.43 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.43 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6904340 | 0.81 | GSK3B (0.50) | — | |
| SCHEMBL6900441 | 0.81 | GSK3B (0.50) | — | |
| SCHEMBL728113 | 0.77 | KMO (1.00) | KMOSLC6A4SLC6A3TSHR | |
| SCHEMBL4386002 | 0.77 | KMO (1.00) | KMOSLC6A4SLC6A3TSHR | |
| SCHEMBL3670421 | 0.77 | KMO (1.00) | KMOSLC6A4SLC6A3TSHR | |
| SCHEMBL19642672 | 0.76 | KMO (0.75) | KMOSLC6A4SLC6A3TSHRHSD11B1 | |
| SCHEMBL4109066 | 0.76 | KMO (0.65) | KMOSLC6A4SLC6A3TSHRHDAC3 | |
| SCHEMBL728316 | 0.75 | KMO (0.69) | KMOSLC6A4SLC6A3TSHRHSD11B1 | |
| SCHEMBL7399080 | 0.75 | KMO (0.69) | KMOSLC6A4SLC6A3TSHRHSD11B1 | |
| SCHEMBL7399077 | 0.75 | KMO (0.69) | KMOSLC6A4SLC6A3TSHRHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12157731-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2024-12-03 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2023-12-14 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | PIC Therapeutics, Inc. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-4114529-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2023-01-11 | — | — | EP | disclosed |
| US-20220356178-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. | 2022-11-10 | — | — | US | disclosed |
| WO-2021178488-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
| WO-2021178488-A1 | EIF4E INHIBITORS AND USES THEREOF | PIC Therapeutics, Inc. (US) | 2021-09-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399322-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | KMO 4572/4885SLC6A4 4170/4885SLC6A3 4437/4885 |
| US-12157731-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | KMO 4572/4885SLC6A4 4170/4885SLC6A3 4437/4885 |
| US-11753403-B2 | EIF4E inhibitors and uses thereof | EIF4E, EIF4EBP1, EIF4A1 | KMO 4572/4885SLC6A4 4170/4885SLC6A3 4437/4885 |
| US-20220356178-A1 | EIF4E INHIBITORS AND USES THEREOF | EIF4E, EIF4EBP1, EIF4A1 | KMO 4572/4885SLC6A4 4170/4885SLC6A3 4437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.